<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160380</url>
  </required_header>
  <id_info>
    <org_study_id>C10953/6270</org_study_id>
    <nct_id>NCT01160380</nct_id>
  </id_info>
  <brief_title>A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma</brief_title>
  <official_title>A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oncotherapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of armodafinil for the treatment of
      cancer-related fatigue in adult patients with multiple myeloma. The study consists of a
      screening period, followed by a 56-day treatment phase, and a final assessment to occur 28
      days after the end of the last treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, multi-center, double-blind, randomized, placebo-controlled, crossover
      study to evaluate the efficacy of armodafinil at a dosage of 150 mg/day for the treatment of
      cancer-related fatigue (CRF) in adult patients with multiple myeloma. The study consists of a
      screening period, followed by a 56 day treatment phase, and a final assessment to occur 28
      days after the end of the last treatment.

      The screening period will occur within 14 days before baseline, where &quot;baseline&quot; refers to
      day 1 when assessments will be made before drug administration. During this period, a medical
      history will be obtained along with a complete physical examination including vital sign
      measurements and Eastern Cooperative Oncology Group (ECOG) performance status. Clinical
      laboratory tests including hematology, clinical chemistry (blood urea nitrogen [BUN], serum
      creatinine, total bilirubin, alkaline phosphatase, aspartate aminotransferase [AST] and
      alanine aminotransferase [ALT]), electrolytes (potassium, sodium, chloride and calcium),
      random glucose, total protein, albumin, and urinalysis will also be performed during the
      screening period as well as serum pregnancy tests for women of childbearing potential.

      During the screening period, patients will also be assessed for the presence of
      cancer-related fatigue using the International Classification for Disease Tenth Edition
      (ICD-10) diagnostic criteria and the Brief Fatigue Inventory (BFI). Only those patients
      showing evidence of cancer-related fatigue will be enrolled in the study. The criteria for
      inclusion for any given patient consist of meeting the International Classification for
      Disease Tenth Edition (ICD-10) criteria for cancer-related fatigue and a score â‰¥ 4 on the
      BFI. ICD-10 CRF classification will be established using a standard interview guide.

      Patients eligible for the study will be randomized to either receive armodafinil at an
      initial fixed dosage of 150 mg/day (Group A) or a placebo (Group B) during the first 28 days
      of the treatment phase. On day 29, patients randomized to receive placebo will then cross
      over to receive armodafinil at a dosage of 150 mg/day until day 56. Group A patients
      randomized to receive armodafinil will continue their current treatment with the drug until
      day 56. The duration of the treatment phase is 56 days.

      Assessments for CRF will be conducted on day 1 (baseline) prior to drug treatment, and after
      drug administration on days 15, 28, 43, and 56. These assessments will be conducted as verbal
      interviews, paper-and-pencil surveys, paper-and-pencil tests, and electronic tests as
      appropriate per assessment.

      During the treatment phase, each patient will also have clinical laboratory tests performed
      on days 1, 15, 28, 43 and 56 to monitor for potential toxicity. Additional procedures
      performed at these visits will include monitoring for adverse events, review of concomitant
      medications and other support therapies (e.g., growth factors and transfusion), ECOG
      performance status, vital signs measurements, and physical examinations.

      Twenty-eight days after the last dose of study drug, patients are to complete a final
      assessment (herein referred to as the end-of-treatment visit). Procedures to be conducted at
      this visit include measurement of vital signs, a complete physical examination, assessment of
      adverse events, a review of concomitant medications, assessment of ECOG performance status,
      hematology and clinical chemistry laboratory tests including electrolytes, total protein and
      albumin. Patients who withdraw from the study before the completion of the 56 day cycle will
      still have all end-of-treatment assessments performed 28 days after their last dose of study
      drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BFI Score</measure>
    <time_frame>Day 1, Day 28 and Day 56</time_frame>
    <description>Survey measuring fatigue. The scale contains 9 items; range=0-90 (0-10 per item). Mild = 1-3 Moderate = 4-7 Severe = 8-10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trail Making Test B Score (TMT-B)</measure>
    <time_frame>Day 1, Day 28 and Day 56</time_frame>
    <description>Cognitive test that gives a measure of various aspects of cognitive performance. Used to measure cognitive fatigue. The test consists of 25 circles containing 13 sequential numbers (1-13) and 12 sequential letters (A-L) positioned.
The test evaluates the time to correctly order letters and numbers; low times = better performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symbol Digit Modalities Test Score (SDMT)</measure>
    <time_frame>Day 1, Day 28 and Day 56</time_frame>
    <description>Test to evaluate neurocognitive functions (attention, visual scanning and motor speed). The test consists of a key =9 graphic symbols numbered 1 to 9 and the test =120 graphic symbols to be matched with its number. The test evaluates the number of correct matches within 90 seconds. Higher scores= better performance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Digit Span Test Score</measure>
    <time_frame>Day 1, Day 28 and Day 56</time_frame>
    <description>Test evaluates working memory and attention. The test consists of repeat numeric sequences of 2 to 9 numbers forward or backwards and evaluates the number of items from a sequence correctly named. Higher scores = better performance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy - Fatigue (FACIT-F) Score</measure>
    <time_frame>Day 1, Day 28 and Day 56</time_frame>
    <description>Survey addressing fatigue and patient happiness, coping, etc. Used to assess quality of life. The test consists of 40 items, each item with a response scale of 0-4. Higher scores denote better status Items are added to provide the total score (range 0-160).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS) Score</measure>
    <time_frame>Day 1, Day 28 and Day 56</time_frame>
    <description>Survey used to assess depression and anxiety. The test consists of 14 items (7 for anxiety and 7 for depression); there are 4 possible answers for each statement. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. Higher scores= more anxiety or depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale (ESS) Score</measure>
    <time_frame>Day 1, Day 28 and Day 56</time_frame>
    <description>Survey assessing sleep patterns. The test consists of 8 items. The response scale range is 0-24 (range 0-3 per item: 0-No chance to falling asleep; 3-high chance of falling asleep). Interpretation: 0-No chance to falling asleep; 10+ above average chance daytime sleepiness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Fatigue</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Armodafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients receive armodafinil for all 56 days of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-First</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>armodafinil</intervention_name>
    <description>Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.</description>
    <arm_group_label>Armodafinil</arm_group_label>
    <arm_group_label>Placebo-First</arm_group_label>
    <other_name>Nuvigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.</description>
    <arm_group_label>Placebo-First</arm_group_label>
    <other_name>sugar-pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has been diagnosed with multiple myeloma based on standard criteria

          -  The patient is diagnosed with cancer-related fatigue based on ICD-10 diagnostic
             criteria

          -  The patient shows signs of severe fatigue as evidenced by a Brief Fatigue Inventory
             score of at least 4

          -  The patient is a man or woman aged 18 years or older at the time of informed consent

          -  The patient has given voluntary written informed consent before any study-related
             procedure is performed which is not part of normal medical care, with the
             understanding that consent may be withdrawn by the patient at any time without
             prejudice to their future medical care

          -  Women of child bearing potential must use a medically accepted method of contraception
             and must agree to continue use of this method for the duration of the study and for 30
             days after participation in the study.

          -  Men must agree to use an acceptable method of contraception throughout the study and
             for 90 days after last dose study drug

          -  The patient must be willing and able to comply with study restrictions

          -  The patient must have an ECOG performance status not greater than 2

          -  The patient must have a life-expectancy of greater than 3 months

          -  The patient must meet the following laboratory criteria within 14 days of enrollment:

               -  Platelet count greater than 50 x 109/L

               -  Absolute neutrophil count greater than 0.5 x 109/L

               -  Hemoglobin greater than 8 g/dL

               -  AST and ALT not greater than 3.0 x the upper limit of normal (ULN)

               -  Serum bilirubin not greater than 2.0 x ULN

               -  Calculated or measured creatinine clearance of at least 10 mL/minute

        Exclusion Criteria:

          -  The patient has been concurrently diagnosed with clinically significant depression

          -  The patient is concurrently enrolled in another investigational study that does not
             apply to the specific treatment of multiple myeloma

          -  The patient is receiving an investigational agent (non-FDA-approved) for any reason
             within 28 days of starting treatment on this study

          -  The patient has previously received armodafinil

          -  The patient has received modafinil or a psychostimulant within 14 days of enrollment

          -  The patient has received a blood transfusion within 14 days of enrollment

          -  The patient has impaired cardiac function or clinically significant cardiac diseases

          -  The patient has other concurrent severe and/or uncontrolled medical or psychiatric
             conditions including abnormal laboratory values, that could cause unacceptable safety
             risks or compromise compliance with the protocol

          -  The patient has known positivity for human immunodeficiency virus (HIV) or hepatitis B
             or C; baseline testing for HIV and hepatitis B or C is not required

          -  The patient has undergone major surgery within 28 days of enrollment or has not
             recovered from side effects of such therapy (Kyphoplasty is not considered to be a
             major surgery; however, the investigator is to discuss enrollment of a patient with a
             recent history of kyphoplasty with Oncotherapeutics' medical monitor)

          -  The patient has a significant history of noncompliance to medical regimens or
             unwilling or unable to comply with the instructions given to him or her by the study
             staff

          -  The patient has a history of skin reactions and/or known sensitivity attributable to
             compounds of similar chemical or biological composition to modafinil, armodafinil, or
             the inactive ingredients in armodafinil including lactose monohydrate, starch,
             microcrystalline cellulose, croscarmellose, sodium, magnesium stearate or povidone

          -  The patient is a pregnant or lactating woman. Any women becoming pregnant during the
             study will be withdrawn from the study

          -  The patient is male whose sexual partner is a woman of childbearing potential not
             using effective birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Berenson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James R. Berenson MD, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center, Inc.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael J. Schlutz, M.D., Inc</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James R. Berenson, MD, Inc.</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <results_first_submitted>October 22, 2014</results_first_submitted>
  <results_first_submitted_qc>November 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2014</results_first_posted>
  <last_update_submitted>November 5, 2014</last_update_submitted>
  <last_update_submitted_qc>November 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer related fatigue</keyword>
  <keyword>fatigue</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>cancer</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Armodafinil</title>
          <description>The patients receive armodafinil for all 56 days of the study.
Armodafinil taken orally at 150 mg daily.</description>
        </group>
        <group group_id="P2">
          <title>Placebo-First</title>
          <description>These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
Placebo taken orally at 150 mg daily. Armodafinil taken orally at 150 mg daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Armodafinil</title>
          <description>The patients receive armodafinil for all 56 days of the study.
armodafinil: Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.</description>
        </group>
        <group group_id="B2">
          <title>Placebo-First</title>
          <description>These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
armodafinil: Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.
Placebo: Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="1.8"/>
                    <measurement group_id="B2" value="67" spread="2.3"/>
                    <measurement group_id="B3" value="65" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG (Eastern Cooperative Oncology Group)</title>
          <description>Grade ECOG Performance status
0 Fully active, performance without restriction
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours
Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
Dead</description>
          <units>paarticipants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fatigue (baseline)-Brief Fatigue Inventory (BFI)</title>
          <description>BFI scale: 9 items; range=0-90 (0-10 per item) Mild = 1-3 Moderate = 4-7 Severe = 8-10</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="39" upper_limit="83"/>
                    <measurement group_id="B2" value="60.5" lower_limit="36" upper_limit="79"/>
                    <measurement group_id="B3" value="60" lower_limit="36" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fatigue (baseline)-International Classification of Diseases version 10 (ICD-10)</title>
          <description>ICD-10 Criteria (Range: 0-14) A1-A11 Fatigue Criteria B. Clinically significant distress or impaired functioning C. Symptoms are a consequence of cancer or cancer therapy D. Symptoms are a consequence of comorbid psychiatric disorders</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9" lower_limit="6" upper_limit="12"/>
                    <measurement group_id="B2" value="9" lower_limit="6" upper_limit="12"/>
                    <measurement group_id="B3" value="9" lower_limit="6" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BFI Score</title>
        <description>Survey measuring fatigue. The scale contains 9 items; range=0-90 (0-10 per item). Mild = 1-3 Moderate = 4-7 Severe = 8-10</description>
        <time_frame>Day 1, Day 28 and Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil</title>
            <description>The patients receive armodafinil for all 56 days of the study.
Armodafinil taken orally at 150 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo-First</title>
            <description>These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
Placebo taken orally at 150 mg daily. Armodafinil taken orally at 150 mg daily.</description>
          </group>
        </group_list>
        <measure>
          <title>BFI Score</title>
          <description>Survey measuring fatigue. The scale contains 9 items; range=0-90 (0-10 per item). Mild = 1-3 Moderate = 4-7 Severe = 8-10</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1(n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" spread="13.2"/>
                    <measurement group_id="O2" value="57.2" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" spread="22.4"/>
                    <measurement group_id="O2" value="41.5" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" spread="18.9"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between arms at Day 28 of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.289</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between Day 1 and Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison between Day 1 and day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison between Day 28 and Day 56 of treatment for the armodafinil arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.449</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trail Making Test B Score (TMT-B)</title>
        <description>Cognitive test that gives a measure of various aspects of cognitive performance. Used to measure cognitive fatigue. The test consists of 25 circles containing 13 sequential numbers (1-13) and 12 sequential letters (A-L) positioned.
The test evaluates the time to correctly order letters and numbers; low times = better performance.</description>
        <time_frame>Day 1, Day 28 and Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil</title>
            <description>The patients receive armodafinil for all 56 days of the study.
Armodafinil taken orally at 150 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo-First</title>
            <description>These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
Placebo taken orally at 150 mg daily. Armodafinil taken orally at 150 mg daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Trail Making Test B Score (TMT-B)</title>
          <description>Cognitive test that gives a measure of various aspects of cognitive performance. Used to measure cognitive fatigue. The test consists of 25 circles containing 13 sequential numbers (1-13) and 12 sequential letters (A-L) positioned.
The test evaluates the time to correctly order letters and numbers; low times = better performance.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1(n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.3" spread="77.8"/>
                    <measurement group_id="O2" value="220.5" spread="163.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.4" spread="81.2"/>
                    <measurement group_id="O2" value="159.8" spread="94.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.8" spread="78.7"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between arms at Day 28 of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.954</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1 vs. Day 28 of treatment for the Placebo-First arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 1 vs. Day 28 of treatment for the Armodafinil arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.369</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison between Day 28 and Day 56 of treatment for the Armodafinil arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.973</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Symbol Digit Modalities Test Score (SDMT)</title>
        <description>Test to evaluate neurocognitive functions (attention, visual scanning and motor speed). The test consists of a key =9 graphic symbols numbered 1 to 9 and the test =120 graphic symbols to be matched with its number. The test evaluates the number of correct matches within 90 seconds. Higher scores= better performance</description>
        <time_frame>Day 1, Day 28 and Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil</title>
            <description>The patients receive armodafinil for all 56 days of the study.
Armodafinil taken orally at 150 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo-First</title>
            <description>These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
Placebo taken orally at 150 mg daily. Armodafinil taken orally at 150 mg daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Symbol Digit Modalities Test Score (SDMT)</title>
          <description>Test to evaluate neurocognitive functions (attention, visual scanning and motor speed). The test consists of a key =9 graphic symbols numbered 1 to 9 and the test =120 graphic symbols to be matched with its number. The test evaluates the number of correct matches within 90 seconds. Higher scores= better performance</description>
          <units>Number of correct matches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1(n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" spread="9.2"/>
                    <measurement group_id="O2" value="40.7" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" spread="12.0"/>
                    <measurement group_id="O2" value="40.8" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7" spread="12.3"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between arms at day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.699</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1 vs. Day 28 of treatment for the Placebo-First arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.984</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 1 vs. Day 28 of treatment for the Armodafinil arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.239</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 28 vs. Day 56 of treatment for the Armodafinil arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.089</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Digit Span Test Score</title>
        <description>Test evaluates working memory and attention. The test consists of repeat numeric sequences of 2 to 9 numbers forward or backwards and evaluates the number of items from a sequence correctly named. Higher scores = better performance.</description>
        <time_frame>Day 1, Day 28 and Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil</title>
            <description>The patients receive armodafinil for all 56 days of the study.
Armodafinil taken orally at 150 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo-First</title>
            <description>These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
Placebo taken orally at 150 mg daily. Armodafinil taken orally at 150 mg daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Digit Span Test Score</title>
          <description>Test evaluates working memory and attention. The test consists of repeat numeric sequences of 2 to 9 numbers forward or backwards and evaluates the number of items from a sequence correctly named. Higher scores = better performance.</description>
          <units>Number of correct items</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Forward-Day 1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="2.7"/>
                    <measurement group_id="O2" value="9.8" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Backward-Day 1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="2.0"/>
                    <measurement group_id="O2" value="6.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forward-Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="3.0"/>
                    <measurement group_id="O2" value="10.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Backward- Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="2.6"/>
                    <measurement group_id="O2" value="7.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forward-Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="2.8"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Backward-Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="2.8"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between arms at Day 28 of treatment for the Digit Span Test score-Forward test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.636</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between arms at Day 28 of treatment for the Digit Span Test score-Backward test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.531</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1 vs. Day 28 of treatment for the Placebo-First arm-Digit Span Test score Forward test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1 vs. Day 28 of treatment for the Placebo-First arm-Digit Span Test score Backward test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.656</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 1 vs. day 28 of treatment for the Armodafinil arm-Digit Span Test score-Forward test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 1 vs. day 28 of treatment for the Armodafinil arm-Digit Span Test score-Backward test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.805</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 28 vs. day 56 of treatment for the Armodafinil arm-Digit Span Test score-Forward test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.692</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 28 vs. day 56 of treatment for the Armodafinil arm-Digit Span Test score-Backward test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.863</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Cancer Therapy - Fatigue (FACIT-F) Score</title>
        <description>Survey addressing fatigue and patient happiness, coping, etc. Used to assess quality of life. The test consists of 40 items, each item with a response scale of 0-4. Higher scores denote better status Items are added to provide the total score (range 0-160).</description>
        <time_frame>Day 1, Day 28 and Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil</title>
            <description>The patients receive armodafinil for all 56 days of the study.
Armodafinil taken orally at 150 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo-First</title>
            <description>These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
Placebo taken orally at 150 mg daily. Armodafinil taken orally at 150 mg daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy - Fatigue (FACIT-F) Score</title>
          <description>Survey addressing fatigue and patient happiness, coping, etc. Used to assess quality of life. The test consists of 40 items, each item with a response scale of 0-4. Higher scores denote better status Items are added to provide the total score (range 0-160).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PWB-Day 1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="3.3"/>
                    <measurement group_id="O2" value="15.3" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SWB-Day 1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="6.7"/>
                    <measurement group_id="O2" value="19.8" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EWB-Day 1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="4.3"/>
                    <measurement group_id="O2" value="17.5" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FWB-Day 1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="3.6"/>
                    <measurement group_id="O2" value="14.6" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue-Day 1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" spread="8.7"/>
                    <measurement group_id="O2" value="18.8" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT-G-Day 1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0" spread="11.6"/>
                    <measurement group_id="O2" value="68.9" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TOI-Day 1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0" spread="12.2"/>
                    <measurement group_id="O2" value="49.4" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total-Day 1 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" spread="15.8"/>
                    <measurement group_id="O2" value="86.1" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PWB-Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="6.6"/>
                    <measurement group_id="O2" value="17.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EWB-Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="5.3"/>
                    <measurement group_id="O2" value="18.7" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SWB-Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="7.5"/>
                    <measurement group_id="O2" value="20.8" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FWB-Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="5.1"/>
                    <measurement group_id="O2" value="16.8" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue-Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" spread="13.22"/>
                    <measurement group_id="O2" value="26.5" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT-G-Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" spread="20.5"/>
                    <measurement group_id="O2" value="75.8" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TOI-Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4" spread="23.5"/>
                    <measurement group_id="O2" value="62.9" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total-Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" spread="31.3"/>
                    <measurement group_id="O2" value="101.3" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PWB-Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="5.1"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EWB-Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" spread="5.7"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SWB-Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="3.4"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FWB-Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="3.8"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue-Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7" spread="9.2"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT-G-Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" spread="12.1"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TOI-Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" spread="14.6"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total-Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.8" spread="18.7"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between arms for Day 28 of treatment- FACIT-F total</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.559</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1 vs. Day 28 of treatment for the Placebo-First arm- FACIT-F total</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 1 vs. Day 28 of treatment for the Armodafinil arm- FACIT-F total</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.192</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 28 vs. Day 56of treatment for the Armodafinil arm- FACIT-F total</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.495</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Anxiety and Depression Scale (HADS) Score</title>
        <description>Survey used to assess depression and anxiety. The test consists of 14 items (7 for anxiety and 7 for depression); there are 4 possible answers for each statement. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. Higher scores= more anxiety or depression.</description>
        <time_frame>Day 1, Day 28 and Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil</title>
            <description>The patients receive armodafinil for all 56 days of the study.
Armodafinil taken orally at 150 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo-First</title>
            <description>These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
Placebo taken orally at 150 mg daily. Armodafinil taken orally at 150 mg daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Anxiety and Depression Scale (HADS) Score</title>
          <description>Survey used to assess depression and anxiety. The test consists of 14 items (7 for anxiety and 7 for depression); there are 4 possible answers for each statement. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. Higher scores= more anxiety or depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety-Day 1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="21.4"/>
                    <measurement group_id="O2" value="8.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression-Day 1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="2.7"/>
                    <measurement group_id="O2" value="7.6" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety-Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="4.6"/>
                    <measurement group_id="O2" value="5.5" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression-Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="17.8"/>
                    <measurement group_id="O2" value="6.6" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety-Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="3.4"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression-Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="2.9"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between arms at Day 28 of treatment- HADS anxiety</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.945</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between arms at Day 28 of treatment- HADS depression</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.316</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1 vs. Day 28 of treatment for the Placebo-First arm-HADS anxiety</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1 vs. Day 28 of treatment for the Placebo-First arm-HADS depression</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 1 vs. Day 28 of treatment for the Armodafinil arm-HADS anxiety</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 1 vs. Day 28 of treatment for the Placebo-First arm-HADS depression</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.315</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 28 vs. Day 56 of treatment for the Armodafinil arm-HADS anxiety</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.933</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 28 vs. Day 56 of treatment for the Armodafinil arm-HADS depression</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.378</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epworth Sleepiness Scale (ESS) Score</title>
        <description>Survey assessing sleep patterns. The test consists of 8 items. The response scale range is 0-24 (range 0-3 per item: 0-No chance to falling asleep; 3-high chance of falling asleep). Interpretation: 0-No chance to falling asleep; 10+ above average chance daytime sleepiness</description>
        <time_frame>Day 1, Day 28 and Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil</title>
            <description>The patients receive armodafinil for all 56 days of the study.
Armodafinil taken orally at 150 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo-First</title>
            <description>These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
Placebo taken orally at 150 mg daily. Armodafinil taken orally at 150 mg daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Epworth Sleepiness Scale (ESS) Score</title>
          <description>Survey assessing sleep patterns. The test consists of 8 items. The response scale range is 0-24 (range 0-3 per item: 0-No chance to falling asleep; 3-high chance of falling asleep). Interpretation: 0-No chance to falling asleep; 10+ above average chance daytime sleepiness</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1(n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="5.1"/>
                    <measurement group_id="O2" value="11.5" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=19, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="5.1"/>
                    <measurement group_id="O2" value="10.0" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="4.5"/>
                    <measurement group_id="O2" value="NA">Day 56 data was only evaluated for the Armodafinil arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between arms for Day 28 of treatment -ESS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.840</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1 vs. Day 28 of treatment for the Placebo-First arm-ESS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 1 and Day 28 of treatment for the Armodafinil arm- ESS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.051</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 28 vs. Day 56 of treatment for the Armodafinil arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.635</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Armodafinil</title>
          <description>The patients receive armodafinil for all 56 days of the study.
Armodafinil taken orally at 150 mg daily. All patients receiving armodafinil, including patients that crossover, were evaluated for adverse events (AEs) and serious adverse events (SAEs).</description>
        </group>
        <group group_id="E2">
          <title>Placebo-First</title>
          <description>These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
Placebo taken orally at 150 mg daily. Armodafinil taken orally at 150 mg daily.
AEs presented were those occurring during from Day 1 to Day 28 only</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ptosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>G3/G4 Leukopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>G3/G4 Lymphopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>G3/G4 Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>G3/G4 Eosinophils (increased)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>G3/G4 Infection (ear)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>G4 Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>G3/G4 Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>G3/G4 Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>G3/G4 Neuroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>G3/G4 BUN (increased)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>G3/G4 Creatinine (increased)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Operations</name_or_title>
      <organization>Oncotherapeutics</organization>
      <phone>310-623-1200</phone>
      <email>lthulin@oncotherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

